Ana C. Garrido-Castro, MD, on Metastatic Breast Cancer: Trial Update on Sacituzumab Govitecan With or Without Pembrolizumab
2024 ASCO Annual Meeting
Ana C. Garrido-Castro, MD, of Dana-Farber Cancer Institute, reports the results from the phase II SACI-IO trial in patients with hormone receptor–positive/HER2-negative metastatic breast cancer who received sacituzumab govitecan-hziy with or without pembrolizumab (LBA1004).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Saci-IO HR+ was a randomized phase II investigator-initiated study to evaluate the efficacy of the trop2 directed antibody drug conjugate sacituzumab govitecan with or without the PD-1 inhibitor pembrolizumab in patients with metastatic hormone receptor-positive HER2 negative breast cancer. SG, sacituzumab govitecan, has demonstrated to improve median progression free and overall survival in patients with previously treated hormone receptor positive HER2 negative breast cancer who have received two to four prior chemotherapies for advanced disease as shown in the TROPiCS-02 study. We know that the payload of sacituzumab govitecan SN38 can enhance cytotoxic T-cell effector functions and deplete regulatory T-cells. It can also stimulate the cGAS-STING pathway increasing T-cell infiltration into the tumor, and thus we hypothesized that the combination of SG plus pembrolizumab would enhance the efficacy of SG alone in metastatic hormone receptor positive HER2 negative breast cancer. Saci-IO HR+ randomized patients one-to-one to receive SG plus pembrolizumab or SG alone in the metastatic hormone receptor positive HER2 negative setting.
Patients had to have received prior endocrine therapy for advanced disease or progressed on or within 12 months of adjuvant endocrine therapy and they could have received 0 to 1 prior lines of chemotherapy in the advanced setting. The primary endpoint of the study was progression-free survival in the intent-to-treat population and key secondary endpoints were progression-free survival among patients with PD-L1 positive tumors defined using the 22C3 assay and a combined positive score greater than or equal than 1, and also overall survival in both the intent-to-treat and PD-L1 positive populations.
The study demonstrated that the addition of pembrolizumab to sacituzumab govitecan did not significantly improve median progression-free survival in the intent-to-treat population. Median PFS with SG plus pembrolizumab was 8.1 months and median PFS with SG alone was 6.2 month, a hazard ratio of 0.81 and P-value of 0.37. In the intent-to-treat population at a median follow-up of 12.5 months, overall survival did not significantly differ between treatment arms. Median OS with SG plus pembrolizumab was 18.5 months versus 18 months with SG alone. And among patients with PD-L1 positive tumors which comprised about 39% of the patient population defined using the CPS cutoff greater than or equal than 1, there was a 4.4 month absolute difference in median progression-free survival between treatment arms favoring the combination that was not statistically significant. Median PFS with SG plus pembrolizumab was 11.1 months and 6.7 months with SG alone, a hazard ratio of 0.62, P-value of 0.23.
Again at a median follow-up of 12.5 months, so overall survival data are not mature, among the patients with PD-L1 positive tumors there was a 6-month numerical increase in median OS with the addition of pembrolizumab to SG. Median OS with the combination was 18.5 months compared to 12.5 months with SG alone.
Overall, the safety profile of SG plus pembrolizumab was similar to that reported with either agent and there were no new safety signals that were reported. In conclusion, Saci-IO HR+ is the first randomized trial to evaluate the efficacy of a topoisomerase 1 inhibitor ADC in combination with an immune checkpoint inhibitor in breast cancer. This study did not show a statistically significant difference in median progression free and overall survival among patients with metastatic hormone receptor positive HER2 negative breast cancer who had received up to one prior line of chemotherapy in the advanced setting. Overall survival data are not mature and additional follow-up is needed.
Among the patients with PD-L1 positive tumors there was a non-significant 4.4 month numerical increase in median PFS and 6-month increase in median OS with the addition of pembrolizumab to SG, and so we do think that the results from this study support further investigation of the combination of SG plus pembrolizumab in patients with PD-L1 positive metastatic hormone receptor positive, HER2 negative breast cancer.
The ASCO Post Staff
Narjust Florez, MD, of the Dana-Farber Cancer Institute, and Suresh S. Ramalingam, MD, of Emory University School of Medicine, Winship Cancer Institute, discuss potentially practice-changing phase III results from the LAURA study. This trial showed that osimertinib after definitive chemoradiation therapy improved progression-free survival for patients with unresectable stage III EGFR-mutated non–small cell lung cancer (NSCLC), suggesting this agent may represent a new standard of care in this setting (LBA4).
The ASCO Post Staff
Yasmin H. Karimi, MD, of the University of Michigan Comprehensive Cancer Center, discusses 2.5-year follow-up data on epcoritamab monotherapy for patients with relapsed or refractory large B-cell lymphoma. The subcutaneous regimen continues to demonstrate durable responses (Abstract 7039).
The ASCO Post Staff
Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center, discusses an ongoing phase III study of the BCL2 inhibitor sonrotoclax plus zanubrutinib vs venetoclax and obinutuzumab for patients with treatment-naive chronic lymphocytic leukemia. The investigators are recruiting internationally (see NCT06073821; Abstract TPS7087).
The ASCO Post Staff
Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center, discusses a network meta-analysis showing that zanubrutinib appears to be the most efficacious Bruton’s tyrosine kinase (BTK) inhibitor for patients with high-risk relapsed or refractory chronic lymphocytic leukemia. It offers delayed disease progression and favorable survival and response, compared with alternative BTK inhibitors (Abstract 7048).
The ASCO Post Staff
Lisa A. Carey, MD, of the University of North Carolina, Chapel Hill and UNC Lineberger Comprehensive Cancer Center, and Dejan Juric, MD, of the Massachusetts General Hospital Cancer Center, discuss phase III findings on first-line use of inavolisib or placebo plus palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor–positive, HER2-negative locally advanced or metastatic breast cancer who relapsed within 12 months of completing adjuvant endocrine therapy (Abstract 1003).